Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sulfonated Bathocuproine Derivatives as Chemically Bonded Buried-Interface Engineers for n-i-p Perovskite Solar Cells.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Recurrent Chondromyxoid Fibroma of the Second Toe Distal Phalanx Treated with Distal Phalangectomy: A Case Report.

Children (Basel, Switzerland)·2026

Same author

Vitamin/mineral and non-vitamin/non-mineral supplement use of breast cancer survivors in Korea.

Nutrition research and practice·2026

Same author

Dosimetric Feasibility of Tomotherapy-Based Selective Axillary Sparing Regional Nodal Irradiation for Lymphedema Risk Reduction in Breast Cancer.

Medicina (Kaunas, Lithuania)·2025

Same author

Cell surface engineering for inhibition of breast cancer cell motility through modulation of mechanotransduction and focal adhesion dynamics.

Journal of tissue engineering·2025

Same author

Correction: Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study.

Frontiers in oncology·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Interdigitating dendritic cell sarcoma occured alone in axilla.

Sun Wook Han¹, Zi Sun Kim, Hyuk Moon Kim

¹Department of Surgery, Soonchunhyang University College of Medicine, Cheonan, Korea.

Journal of the Korean Surgical Society

|May 8, 2012

Summary

This summary is machine-generated.

Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive cancer. This case study details a patient successfully treated with radiotherapy for axillary IDCS, showing no recurrence after 13 months.

Keywords:

Axilla Interdigitating dendritic cell sarcoma

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: May 22, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Oncology
Pathology

Background:

Interdigitating dendritic cell sarcoma (IDCS) is an exceptionally rare and aggressive neoplastic disease.
Diagnosis and treatment of IDCS present significant challenges due to its rarity and rapid progression.

Observation:

A 57-year-old female presented with a hard, fixed left axillary mass.
Computed tomography revealed a 7 cm left axillary lymph node; core biopsy suggested sarcoma.

Findings:

Pathological examination following left axillary lymph node dissection confirmed Interdigitating dendritic cell sarcoma.
The patient received radiotherapy as the sole treatment for the axillary IDCS.

Implications:

The patient remained recurrence-free for 13 months post-radiotherapy, indicating a potential treatment avenue.
Further research and accumulated clinical experience are crucial for establishing optimal treatment strategies for IDCS.